Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
7.06
+0.31 (4.59%)
At close: Aug 19, 2026, 4:00 PM EDT
7.18
+0.12 (1.70%)
After-hours: Aug 19, 2026, 6:54 PM EDT
Foghorn Therapeutics Employees
Foghorn Therapeutics had 106 employees as of December 31, 2025. The number of employees decreased by 6 or -5.36% compared to the previous year.
Employees
106
Change (1Y)
-6
Growth (1Y)
-5.36%
Revenue / Employee
$346,594
Profits / Employee
-$609,236
Market Cap
419.26M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 106 | -6 | -5.36% |
| Dec 31, 2024 | 112 | -4 | -3.45% |
| Dec 31, 2023 | 116 | -45 | -27.95% |
| Dec 31, 2022 | 161 | 42 | 35.29% |
| Dec 31, 2021 | 119 | 24 | 25.26% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ProKidney | 231 |
| EyePoint | 214 |
| Scribe Therapeutics | 89 |
| Upstream Bio | 75 |
| Lexeo Therapeutics | 63 |
| Atea Pharmaceuticals | 55 |
| X4 Pharmaceuticals | 45 |
| Compass Therapeutics | 39 |
FHTX News
- 13 days ago - Foghorn Therapeutics reports Q2 EPS (10c), consensus (23c) - TheFly
- 13 days ago - Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update - GlobeNewsWire
- 13 days ago - Foghorn Therapeutics Quarterly report: Q2 2026 - Filings
- 13 days ago - Foghorn Therapeutics Earnings release: Q2 2026 - Filings
- 13 days ago - Foghorn Therapeutics Slides: Investor presentation - Filings
- 7 weeks ago - Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - GlobeNewsWire